Trial Profile
A phase I/II study of LentiGlobin (HPV569) in patients with beta-thalassaemia major or sickle cell anaemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Jul 2014
Price :
$35
*
At a glance
- Drugs Betibeglogene-autotemcel (Primary)
- Indications Beta-thalassaemia; Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors bluebird bio
- 01 Jul 2014 New trial record
- 15 Jun 2014 Results presented at the 19th Congress of the European Haematology Association.